Weekly Analysts’ Ratings Changes for CRISPR Therapeutics (CRSP)

Several brokerages have updated their recommendations and price targets on shares of CRISPR Therapeutics (NASDAQ: CRSP) in the last few weeks:

• 5/27/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 5/13/2026 – CRISPR Therapeutics had its price target raised by Sanford C. Bernstein from $50.00 to $56.00. They now have a “market perform” rating on the stock.
• 5/11/2026 – CRISPR Therapeutics had its “outperform” rating reaffirmed by Evercore Inc. They now have a $76.00 price target on the stock.
• 5/9/2026 – CRISPR Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/6/2026 – CRISPR Therapeutics had its price target raised by Citigroup Inc. from $80.00 to $82.00. They now have a “buy” rating on the stock.
• 4/20/2026 – CRISPR Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,150 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $152,019.00. Following the completion of the sale, the insider directly owned 13,143 shares in the company, valued at approximately $634,281.18. This trade represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 3,182 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $148,853.96. Following the completion of the sale, the general counsel owned 94,308 shares of the company’s stock, valued at approximately $4,411,728.24. This trade represents a 3.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 42,749 shares of company stock worth $2,100,723. 4.30% of the stock is owned by insiders.

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.